CIDRAP newsletters options
More than 750 have died from Ebola in the past 2 months.
Currently 12 patients are hospitalized for Legionnaires’ disease.
The concerning trend appears to be driven by parents refusing vitamin K shots, which guard against a rare but life-threatening blood disorder, for their newborns.
As the outbreak continues, identifying the source of Cyclospora remains a challenge.
Although many consider measles a mild disease, this report describes 49 patients who required hospital care, 8% of the total.
Sen. Mitch McConnell is one of up to 300,000 Americans living with post-polio syndrome, a set of symptoms that occur decades after the original infection.
The antiviral would be given as post-exposure prevention.
The case-fatality rate this year is now 24%.
The overall incidence of Clostridioides difficile infections among ED patients declined from 2014 to 2024, although rates in young adults increased.
A second American has contracted Ebola in the Democratic Republic of the Congo, and the death count has now topped 700.
A new work requirement rule goes into effect in January. Experts anticipate higher rates of HIV transmission.
Taking analgesics like NSAIDS or Tylenol prior to receiving a flu vaccine has minimal to no effect on antibody production and the risk of developing flu.
A new study finds that while severe symptoms usually fade within a week, milder symptoms can persist for up to a month.
A study of 6 African nations finds urinary tract isolates are highly resistant to first-line and broader-spectrum antibiotics.
Michigan officials confirm more than 2,600 cyclosporiasis cases.
A WHO official warns the outbreak could be 2 to 4 times larger than the number of confirmed cases, which are now around 1,800.
The study highlights how shelters can experience infectious disease outbreaks and how they can be prevented.
The FDA has issued emergency authorizations for several treatments that may also prevent infestations.
A Mayo Clinic study finds the risk is almost doubled for adults under 50, a group currently not broadly advised to get an RSV vaccine.
The findings of a clinical trial may help fill a healthcare gap for the 1% to 5% of adults worldwide who experience long COVID.
